For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | 2,000,000* | - | 0 |
| Cost of revenue | - | 1,987,000* | - | 0 |
| Gross profit | - | 13,000* | - | 0 |
| Research and development expenses | 1,594,000 | 3,100,500* | 1,153,000 | 1,034,000 |
| General and administrative expenses | 2,065,000 | 4,626,500* | 1,274,000 | 1,455,000 |
| Operating loss | -3,659,000 | -7,714,000* | -2,427,000 | -2,489,000 |
| Other income, net | 8,250,000 | -39,500* | 408,000 | 257,000 |
| Financial income (gain), net | 44,849,000 | -25,800,000* | 61,470,000 | 15,366,000 |
| Interest expenses | - | - | - | 0 |
| Income (gain) before tax expenses | 49,440,000 | -33,553,500* | 59,451,000 | 13,134,000 |
| Tax expenses | 11,130,000 | -5,096,000* | 11,062,000 | -126,000 |
| Net income (gain) | - | -28,457,500* | 48,389,000 | 13,260,000 |
| Non-controlling interests | - | 17,000* | -6,000 | -28,000 |
| Net income (gain) | 38,310,000 | -28,474,500 | 48,395,000 | 13,288,000 |
| Basic EPS | 0.94 | -0.699 | 1.16 | 0.32 |
| Diluted EPS | 0.91 | -0.68 | 1.13 | 0.31 |
| Basic Average Shares | 40,773,866 | 40,709,204 | 41,756,301 | 41,743,486 |
| Diluted Average Shares | 41,970,186 | 41,872,003 | 42,774,504 | 42,609,425 |
ORAMED PHARMACEUTICALS INC. (ORMP)
ORAMED PHARMACEUTICALS INC. (ORMP)